TICKERNERD
Menu
ALMRHealthcare · Medical Devices

ALMR Stock Forecast: Alamar Biosciences, Inc. (California) Price Predictions for 2026-2027

Last close, 3 Aug 2026
$27
+6.74% on the day

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) hold a median 12-month price target of $32 — +18.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.8B
Ticker Nerd rank
1 / 100
Median analyst target
$32
Analysts covering
5
Total return, dividends reinvested
1W
+10.9%
1M
+4.4%
From high
−4.8%
From low
+41.8%
$19
$28
Range since 17 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

ALMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alamar Biosciences, Inc. (California) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
1 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
38
Revisions
37
Momentum
12
Value
10
Growth
8
Accruals
8
Volatility
3
Quality
3
Issuance
0

Size (38): Smaller than most of the companies we track.

Issuance (0): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Alamar Biosciences, Inc. (California) — and when they’d sell — is the membership.

Wall Street

ALMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Apr 2026Adjusted close, US dollars
$20$25$30$35May 26Jun 26Jul 26Aug 26ALMRHigh $35Median $32Low $28

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts
4 Buy1 Hold0 Sell
Low $28Median $32High $35

The green dot is the last close — the median target sits +18.2% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 May 2026JP MorganInitiatesOverweight$30
12 May 2026Leerink PartnersInitiatesOutperform$35
12 May 2026StifelInitiatesBuy$28
12 May 2026TD CowenInitiatesBuy$30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

ALMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Alamar Biosciences, Inc. (California) (ALMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−56.7×

Cheaper than 98% of US stocks

Price / sales
20.2×

Cheaper than 9% of US stocks

Price / book
−9.3×

Cheaper than 97% of US stocks

EV / EBITDA
−63.4×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
98.9%

Higher than 93% of US stocks

Earnings growth (YoY)
—
Gross margin
55.5%

Higher than 70% of US stocks

Operating margin
−47.4%

Higher than 18% of US stocks

Net margin
−49.9%

Higher than 10% of US stocks

Returns & dividend
Return on equity
18.8%

Higher than 80% of US stocks

Return on assets
−21.3%

Higher than 19% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
ALMRAlamar Biosciences, Inc. (California)$1.8B
1
NVCRNovoCure Ltd.$1.7B
94
ENOVEnovis Corp.$1.7B
80
BFLYButterfly Network, Inc.$1.9B
72
UFPTUFP Technologies, Inc.$2.0B
74
AHCOAdaptHealth Corp.$1.5B
81
ATECAlphatec Holdings, Inc.$1.4B
75
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest ALMR news & analysis

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome

GlobeNewsWire · 28 July 2026positive

Alamar Biosciences launched the NULISAseq™ Immune 340 Panel, an expanded panel designed for comprehensive profiling of the immune proteome in translational and clinical research.

Why it matters — ALMR watchers would care because the new panel could strengthen the company's position in the immunoproteomics market, with potential applications across cancer, cardiovascular, metabolic, autoimmune, and aging research.

FAQ

Frequently asked questions about ALMR stock

What is the ALMR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) have a median 12-month price target of $32, with estimates ranging from $28 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALMR stock a buy right now?

Of the 5 analysts covering Alamar Biosciences, Inc. (California), 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alamar Biosciences, Inc. (California) 1 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALMR?

As at 1 Aug 2026, Alamar Biosciences, Inc. (California) ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (38 of 100).

Will ALMR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +18.2% from the last close, and Ticker Nerd's factor model ranks Alamar Biosciences, Inc. (California) 1 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALMR stock forecast for 2030?

No analyst covering Alamar Biosciences, Inc. (California) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $28 to $35 over the next 12 months.

What does Alamar Biosciences, Inc. (California) do?

Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies.

What is the latest news on ALMR?

The most recent item we track (GlobeNewsWire, 28 July 2026): "Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome". Alamar Biosciences launched the NULISAseq™ Immune 340 Panel, an expanded panel designed for comprehensive profiling of the immune proteome in translational and clinical research.

Company

About Alamar Biosciences, Inc. (California).

Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies. It develops and commercializes the proprietary NULISA platform, designed to overcome limitations of traditional proteomics tools by enabling detection of protein biomarkers at extremely low concentrations in non-invasive biological fluids like blood. Key features include ultra-high sensitivity, high specificity, flexible multiplexing capabilities, broad dynamic range, and seamless automation, establishing a gold standard for precision proteomics. The company serves the healthcare sector, particularly the medical devices industry, by providing tools for disease detection research, including early identification of cancer and other diseases through protein biomarker platforms. Alamar Biosciences, Inc. focuses on powering precision medicine applications in research and diagnostics. Founded in 2018 and headquartered in Fremont, California, it plays a significant role in advancing proteomics for biological and clinical research.

CEO Dr. Yuling Luo Ph.D. · 222 employees · United States · https://alamarbio.com